JTT 252

Drug Profile

JTT 252

Alternative Names: JTT-252

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Akros Pharma
  • Class Antihyperglycaemics
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Aug 2015 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
  • 30 Apr 2015 Akros Pharama terminates a phase I trial in Diabetes mellitus in USA (PO) (NCT02120976)
  • 01 Apr 2014 Phase-I clinical trials in Type-2 Diabetes mellitus in USA (PO) (NCT02120976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top